Sun Pharmaceutical shares gain on US nod for cancer drug 'Doxil'

Sun Pharmaceutical Industries Ltd shares rose as much as 4.5 percent after the U.S. Food and Drug Administration approved its generic version of ovarian cancer drug Doxil made by Johnson & Johnson in the U.S. market.

* "Doxil generic approval came in as a positive surprise. This would add US$70-$100m in high margin sales for FY14 until further generic competition comes in," CLSA said in a note on Tuesday.